All Stories

Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant

Aurobindo's Aurolife Pharma has received a Form 483 from the FDA outlining 11 observations at the company's North Carolina inhaler plant, the drugmaker said in a filing.

Apr 14, 2025 - 20:06
 0
Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant
Aurobindo's Aurolife Pharma has received a Form 483 from the FDA outlining 11 observations at the company's North Carolina inhaler plant, the drugmaker said in a filing.
Read More

Tags:

Previous Article

Older People Seeking Care for Cannabis Use at Greater Risk for Dementia

Next Article

APES unveils Matrix6D at RAPID + TCT 2025: Modular, software-defined factory pla...

Related Posts

#FierceMadness: Heavyweights face off in Elite Eight round of the 2025 Drug Ad Tournament—VOTE NOW

#FierceMadness: Heavyweights face off in Elite Eight ro...

Mar 25, 2025  0

Novartis pumps $7.5M into push to save 100,000 lives from prostate cancer by 2035

Novartis pumps $7.5M into push to save 100,000 lives fr...

Feb 19, 2025  0

With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors

With Teva competition heating up, Neurocrine's tame Ing...

Feb 10, 2025  0